- $221.21m
- $154.31m
- $408.52m
- 38
- 64
- 83
- 65
Annual income statement for Nevro, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 362 | 387 | 406 | 425 | 409 |
| Cost of Revenue | |||||
| Gross Profit | 250 | 266 | 276 | 290 | 271 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 425 | 498 | 400 | 521 | 535 |
| Operating Profit | -63.3 | -111 | 6.16 | -95.4 | -126 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -82.2 | -131 | 4.26 | -97.9 | -112 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -83.1 | -131 | 3 | -92.2 | -113 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -83.1 | -131 | 3 | -92.2 | -113 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -83.1 | -131 | 3 | -92.2 | -113 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.35 | -3.32 | -1.76 | -2.6 | -2.12 |